Literature DB >> 1641253

On the distribution of a fluorescent ivermectin probe (4" 5,7 dimethyl-bodipy proprionylivermectin) in Ascaris membranes.

R J Martin1, J R Kusel.   

Abstract

The distribution of the fluorescent ivermectin derivative (4" 5,7 dimethyl bodipy proprionylivermectin, referred to here as bodipy ivermectin) was studied in muscle vesicle membranes from the parasite Ascaris suum. Incubation in bodipy ivermectin, at concentrations greater than 1 ng/ml, produced a dose-dependent fluorescence in the vesicles. The level of fluorescence was not depressed (but increased) by prior incubation with 1 microM unlabelled ivermectin. This observation suggested that most of the bodipy ivermectin was free in the lipid phase of the membrane and not associated with a receptor. The trypan blue quenching technique showed that the bodipy ivermectin did not cross the membrane bilayer but remained in the outer monolayer. Lateral mobility of the probe in the membrane was studied using the fluorescence recovery after photobleaching (FRAP) technique. The lateral diffusion coefficient (DL) was 14.0 x 10(-10) cm2/s which was nearly three times faster than the lipid probe octadecanoyl-aminofluorescein in membranes from the same preparations; only 46% of the probe was mobile, showing that within a 1.2 microns radius the distribution of the bodipy ivermectin in the membrane was not homogeneous. These observations are used to suggest that: the site of action of ivermectin is located in the outer monolayer of the membrane (possibly on the Cl- channel); and that the speed of onset of action in isolated membrane preparations may be limited by diffusion in the membrane.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641253     DOI: 10.1017/s0031182000063812

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  8 in total

1.  Derquantel and abamectin: effects and interactions on isolated tissues of Ascaris suum.

Authors:  Sreekanth Puttachary; Sasa M Trailovic; Alan P Robertson; David P Thompson; Debra J Woods; Richard J Martin
Journal:  Mol Biochem Parasitol       Date:  2013-03-21       Impact factor: 1.759

2.  Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors.

Authors:  W Nörenberg; H Sobottka; C Hempel; T Plötz; W Fischer; G Schmalzing; M Schaefer
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 3.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

4.  Curiouser and Curiouser: The Macrocyclic Lactone, Abamectin, Is also a Potent Inhibitor of Pyrantel/Tribendimidine Nicotinic Acetylcholine Receptors of Gastro-Intestinal Worms.

Authors:  Melanie Abongwa; Samuel K Buxton; Alan P Robertson; Richard J Martin
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

5.  Trapping of ivermectin by a pentameric ligand-gated ion channel upon open-to-closed isomerization.

Authors:  Nurit Degani-Katzav; Moshe Klein; Moran Har-Even; Revital Gortler; Ruthi Tobi; Yoav Paas
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

6.  Effects of glutamate and ivermectin on single glutamate-gated chloride channels of the parasitic nematode H. contortus.

Authors:  Mohammed Atif; Argel Estrada-Mondragon; Bindi Nguyen; Joseph W Lynch; Angelo Keramidas
Journal:  PLoS Pathog       Date:  2017-10-02       Impact factor: 6.823

7.  GluClR-mediated inhibitory postsynaptic currents reveal targets for ivermectin and potential mechanisms of ivermectin resistance.

Authors:  Mohammed Atif; Jennifer J Smith; Argel Estrada-Mondragon; Xue Xiao; Angela A Salim; Robert J Capon; Joseph W Lynch; Angelo Keramidas
Journal:  PLoS Pathog       Date:  2019-01-29       Impact factor: 6.823

8.  Molecular mechanisms of Cys-loop ion channel receptor modulation by ivermectin.

Authors:  Timothy Lynagh; Joseph W Lynch
Journal:  Front Mol Neurosci       Date:  2012-05-07       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.